Directing an mRNA-LNP vaccine toward lymph nodes improves humoral and cellular immunity against SARS-CoV-2
D. M. Francis, R. Chen, S. Khorsandzadeh, Q. Hu, X. Lyu, H. Wang, W.-l. Lim, H. Sun, H. Xie, N. Shaabani, R. Ross, B. Cooley, H. Ji
This study develops an mRNA-LNP vaccine (STI-7264) and a lymphatic delivery device (MuVaxx) that enhance immune responses against SARS-CoV-2 with reduced dosing.
bioRxiv · Aug 25, 2021 · PreprintImmunology